돼지 모델에서 Ex-Situ Heart Perfusion 중 관상 동맥 조영술

Executive Industry Relevance

Coronary angiography during ex-situ heart perfusion in a porcine model addresses a critical gap in donor heart screening, particularly for extended criteria donors at risk for coronary artery disease. By enabling reproducible, quantitative coronary imaging outside the body, this protocol supports more confident graft selection and reduces the risk of primary graft failure. Integrating this approach at the procurement stage can enhance predictive confidence and optimize portfolio advancement decisions in transplantation research.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct interrogation of coronary artery patency in donor hearts prior to transplantation.
• Supports biological de-risking by identifying subclinical coronary lesions in marginal grafts.
• Facilitates functional validation of donor heart viability through quantitative imaging and lactate extraction metrics.
• Improves predictive confidence for downstream transplantation outcomes.

Screening & Assay Development

• Establishes standardized, reproducible imaging views for coronary assessment in ex-situ perfused hearts.
• Provides quantitative outputs such as contrast agent volume and lactate concentration for assay comparability.
• Enables reliable exclusion of significant coronary stenosis prior to graft acceptance.
• Supports scalability and platform reuse for broader donor screening initiatives.

Translational & Preclinical Research

• Aligns with disease-relevant models by simulating clinical donor heart evaluation workflows.
• Ensures continuity from preclinical imaging validation to translational transplantation protocols.
• Reduces biological risk in preclinical-to-clinical transition by standardizing viability assessment.
• Provides mechanistic de-risking for organ selection strategies.

Pipeline & Workflow Integration

This protocol integrates at the interface of donor heart procurement and preclinical transplantation validation, bridging early discovery with translational research.

• Discovery Biology: Supports hypothesis testing regarding coronary disease prevalence in marginal donors and clarifies viability thresholds.
• Screening: Delivers reproducible, quantitative coronary imaging outputs for standardized donor assessment.
• Analytics: Enables measurement of lactate extraction and contrast agent exposure to inform viability and safety decisions.
• Translational Research: Provides a workflow-aligned model for preclinical validation of donor heart selection criteria.
• Enterprise Reuse: Offers a reusable imaging and assessment protocol adaptable across donor models and research settings.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in donor heart selection and reduces mechanistic ambiguity in graft viability.
• Operational Value: Standardizes coronary imaging and viability assessment for reproducibility and scalability.
• Strategic Value: Enables more informed go/no-go decisions, improving capital efficiency and reducing late-stage biological risk in transplantation research.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of donor hearts for transplantation studies.

Implementation Considerations

• Requires expertise in interventional cardiology and ex-situ perfusion techniques.
• Demands access to specialized perfusion modules and imaging instrumentation.
• Necessitates cross-team standardization of imaging views and viability metrics.
• May require adaptation for different donor species or perfusion platforms.
• Contrast agent retention and imaging artifacts must be managed to ensure data quality.

Biopharma FAQs